<DOC>
	<DOCNO>NCT02919371</DOCNO>
	<brief_summary>Combined sunitinib bevacizumab advance renal cell carcinoma .</brief_summary>
	<brief_title>Combined Alternating Sunitinib Bevacizumab ( Avastin® ) Advanced Renal Cell Carcinoma ( CASA )</brief_title>
	<detailed_description>This phase I/II trial combine sunitinib bevacizumab advance renal cell carcinoma ( CASBA ) Bevacizumab use day 29 6 week sunitinib cycle .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<criteria>1 . Histologically confirm renal cell carcinoma clear cell histology ( mixed histology clear cell component accept ) 2 . Patient either locally advanced metastatic disease 3 . No prior anticancer therapy 4 . Age ≥ 18 year 5 . Life expectancy 3 month 6 . Measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) criteria version 1.1 7 . Performance status 02 ECOG scale 8 . Patients control brain metastasis accept 9 . Adequate renal function : serum creatinine ≤ 2 time institutional upper limit normal 10 . Adequate hepatic function : total bilirubin within normal institutional limit , serum AST ALT level ≤2 time institutional upper limit normal ≤ 5 time institutional upper limit normal elevate liver involvement 11 . Coagulation ( PT ≤ 1.5 time institutional upper limit normal ) 12 . Adequate hematological value : leukocyte count ≥3.0 x 109/L , absolute neutrophil count ≥1.5 x 109/L , platelet count ≥100 x 109/L hemoglobin ≥ 9.0 g/dL 13 . Urine dipstick proteinuria &lt; 1+ , patient discover ≥ 1+ dipstick urinanalysis baseline urine protein/urine creatinine ratio ≤1 14 . Singed write informed consent enrolment 15 . Patient unresectable disease ( primary tumor metastasis ) 1 . Inability comply protocol therapy 2 . Uncontrolled hypertension define BP 160 systolic 100 diastolic despite adequate treatment time treatment initiation . 3 . Severe cardiovascular disease ( congestive heart failure NYHA III IV , unstable angina pectoris , myocardial infarction , significant arrhythmias Transient ischemic attack ( TIA ) cerebrovascular accident ( CVA ) last 6 month 4 . Major bleed disorder , significant traumatic injury recent major surgery within 28 day start therapy . Or minor surgery ( FNA/Core biopsy ) within 7 day start therapy 5 . History abdominal abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month 6 . Preexisting thyroid abnormality 7 . Concurrent proarrhythmic medication include terfenadine , quinidine , procainamide , disopyramide , sotalol , bepridil , haloperidol , risperidone , indapamide flecainide 8 . Recent significant hemoptysis ( 1/2 tea spoon red blood within last month ) 9 . Concurrent medication either CYP 450 3A4 inducer inhibitor 10 . Concurrent use proarrhythmic medication include terfenadine , quinidine , procainamide , disopyramide , sotalol , probucol , bepridil , haloperidol , risperidone , indapamide flecainide 11 . Pregnancy breast feeding , patient refusal use appropriate contraception female patient childbirth age 12 . Previous malignancy within 5 year , except adequately treat non melanomatous skin cancer situ cervical cancer 13 . Psychiatric mental disorder , preclude understand information trial related topic give valid informed consent 14 . Any psychological , familial , geographic social circumstance could impair patient ability participate trial comply follow . 15 . Any circumstance might impair patient 's ability comply outpatient regimen 16 . Active uncontrolled infection 17 . Serious underlie medical condition ( judgment investigator ) could impair ability patient participate trial 18 . Treatment experimental drug within 30 day entry trial 19 . Treatment anticancer therapy 20 . Legal incapacity 21 . Significant proteinuria ( urine protein : creatinine ratio &gt; 1.0 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>